$PIRS
Pieris Pharmaceuticals Inc

2024 Q3 Form 10-Q Financial Statement

#000143774924026778 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2
Revenue $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.426M
YoY Change -6.5%
% of Gross Profit
Research & Development $751.0K
YoY Change -94.76%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $4.177M
YoY Change -76.78%
Operating Profit -$4.177M
YoY Change -302.47%
Interest Expense $201.0K
YoY Change -58.98%
% of Operating Profit
Other Income/Expense, Net $386.0K
YoY Change -339.75%
Pretax Income -$3.590M
YoY Change -190.29%
Income Tax
% Of Pretax Income
Net Earnings -$3.590M
YoY Change -190.29%
Net Earnings / Revenue
Basic Earnings Per Share -$2.76
Diluted Earnings Per Share -$2.76
COMMON SHARES
Basic Shares Outstanding 1.320M 1.320M
Diluted Shares Outstanding 1.299M

Balance Sheet

Concept 2024 Q3 2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.73M
YoY Change -64.04%
Cash & Equivalents $19.73M
Short-Term Investments $0.00
Other Short-Term Assets $649.0K
YoY Change -93.9%
Inventory
Prepaid Expenses
Receivables $1.485M
Other Receivables $137.0K
Total Short-Term Assets $25.05M
YoY Change -62.31%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $25.05M
Total Long-Term Assets $0.00
Total Assets $25.05M
YoY Change -71.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $969.0K
YoY Change -87.26%
Accrued Expenses $4.364M
YoY Change -49.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.346M
YoY Change -81.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $6.346M
Total Long-Term Liabilities $0.00
Total Liabilities $6.346M
YoY Change -86.51%
SHAREHOLDERS EQUITY
Retained Earnings -$323.4M
YoY Change 7.94%
Common Stock $1.000K
YoY Change -98.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $18.71M
YoY Change
Total Liabilities & Shareholders Equity $25.05M
YoY Change -71.38%

Cashflow Statement

Concept 2024 Q3 2024 Q2
OPERATING ACTIVITIES
Net Income -$3.590M
YoY Change -190.29%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.480M
YoY Change -88.98%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $2.176M
YoY Change -267.51%
Cash From Investing Activities $2.176M
YoY Change -259.3%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.480M
Cash From Investing Activities 2.176M
Cash From Financing Activities 0.000
Net Change In Cash 696.0K
YoY Change -86.04%
FREE CASH FLOW
Cash From Operating Activities -$1.480M
Capital Expenditures $0.00
Free Cash Flow -$1.480M
YoY Change -89.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
dei Entity Central Index Key
EntityCentralIndexKey
0001583648
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
700000 usd
CY2024Q2 pirs Increase In Contract With Customer Liability
IncreaseInContractWithCustomerLiability
0 usd
pirs Increase In Contract With Customer Liability
IncreaseInContractWithCustomerLiability
0 usd
CY2024Q2 pirs Decrease In Contract With Customer Liability
DecreaseInContractWithCustomerLiability
0 usd
pirs Decrease In Contract With Customer Liability
DecreaseInContractWithCustomerLiability
0 usd
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
14200000 eur
CY2024Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
CY2023Q2 us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
0 usd
us-gaap Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
100000 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
200000 usd
CY2024Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
200000 usd
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3750000
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1320240
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1236688
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15617
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
15617
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15617
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
0 usd
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37471
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
30-0784346
dei Entity Address Address Line1
EntityAddressAddressLine1
225 Franklin Street, 26th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Boston
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02110
dei City Area Code
CityAreaCode
857
dei Local Phone Number
LocalPhoneNumber
246-8998
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value per share
dei Trading Symbol
TradingSymbol
PIRS
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
1320240
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19731000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17396000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
0 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
8970000 usd
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1485000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
572000 usd
CY2024Q2 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3049000 usd
CY2023Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
3141000 usd
CY2024Q2 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
137000 usd
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2326000 usd
CY2024Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0 usd
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
2188000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
649000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4087000 usd
CY2024Q2 us-gaap Assets
Assets
25051000 usd
CY2023Q4 us-gaap Assets
Assets
38680000 usd
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
969000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3372000 usd
CY2024Q2 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
5377000 usd
CY2023Q4 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8550000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6346000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11922000 usd
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1000 usd
CY2024Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
342586000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
341693000 usd
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-436000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-323446000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-314964000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
18705000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26758000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25051000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
38680000 usd
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0 usd
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
20086000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
6000 usd
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
22096000 usd
CY2024Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0 usd
CY2023Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
-31000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
47000 usd
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
-105000 usd
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
20055000 usd
us-gaap Revenues
Revenues
53000 usd
us-gaap Revenues
Revenues
21991000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
751000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14328000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1969000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27752000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3426000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3664000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7564000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7687000 usd
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
4177000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17992000 usd
us-gaap Operating Expenses
OperatingExpenses
9533000 usd
us-gaap Operating Expenses
OperatingExpenses
35439000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4177000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
2063000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9480000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-13448000 usd
CY2024Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
201000 usd
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
490000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
441000 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
847000 usd
CY2024Q2 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
0 usd
CY2023Q2 us-gaap Government Assistance Amount
GovernmentAssistanceAmount
1584000 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
0 usd
us-gaap Government Assistance Amount
GovernmentAssistanceAmount
3612000 usd
CY2024Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
386000 usd
CY2023Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-161000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
557000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-218000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3590000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3976000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8482000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
CY2024Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-90000 usd
CY2023Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
287000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-463000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
45000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
2000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-1000 usd
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
72000 usd
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3680000 usd
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
4265000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8946000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9090000 usd
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.76
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.08
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.08
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1299000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1095000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1268000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1014000
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1299000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1098000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1268000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1014000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15458000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3976000 usd
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1048000 usd
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
287000 usd
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
2000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40498000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
21964000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3590000 usd
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
421000 usd
CY2024Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-90000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
18705000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
27929000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1932000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
45000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
72000 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
52000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
40498000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
26758000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8482000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
893000 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-463000 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-1000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
18705000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8482000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
-30000 usd
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
1363000 usd
pirs Operating Lease Right Of Use Asset Accretion
OperatingLeaseRightOfUseAssetAccretion
-0 usd
pirs Operating Lease Right Of Use Asset Accretion
OperatingLeaseRightOfUseAssetAccretion
67000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
893000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1932000 usd
pirs Proceeds From Sale Of Fixed Assets Operating Activities
ProceedsFromSaleOfFixedAssetsOperatingActivities
-219000 usd
pirs Proceeds From Sale Of Fixed Assets Operating Activities
ProceedsFromSaleOfFixedAssetsOperatingActivities
0 usd
pirs Noncash Adjustment Prepaid Rent
NoncashAdjustmentPrepaidRent
1112000 usd
pirs Noncash Adjustment Prepaid Rent
NoncashAdjustmentPrepaidRent
0 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-0 usd
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
53000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-21000 usd
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
110000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
1771000 usd
us-gaap Increase Decrease In Operating Capital
IncreaseDecreaseInOperatingCapital
18285000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8476000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24427000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
-0 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
115000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
9000000 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
18895000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
2176000 usd
us-gaap Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
0 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
-0 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
8243000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
11176000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
10537000 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
0 usd
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
52000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
19729000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19781000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-365000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
412000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
2335000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
6303000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
17396000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38635000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19731000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
44938000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-1000 usd
us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
72000 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
74000 usd
CY2023Q3 pirs Reduction In Workforce Percentage
ReductionInWorkforcePercentage
0.70 pure
CY2023Q4 pirs Reduction In Workforce Cost
ReductionInWorkforceCost
7500000 usd
CY2024Q2 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
19700000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3600000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
4000000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8500000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9200000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-323400000 usd
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Concentration of Credit Risk and Off-Balance Sheet Risk</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has <em style="font: inherit;">no</em> financial instruments with off-balance sheet risk such as foreign exchange contracts, option contracts or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments and defines allowable investments that the Company believes minimize the exposure to concentration of credit risk. The Company has <em style="font: inherit;">not</em> experienced any credit losses in such accounts and does <em style="font: inherit;">not</em> believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does <em style="font: inherit;">not</em> obtain collateral.</p> <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"> </p>
CY2024Q2 us-gaap Revenues
Revenues
0 usd
CY2023Q2 us-gaap Revenues
Revenues
20055000 usd
us-gaap Revenues
Revenues
53000 usd
us-gaap Revenues
Revenues
21991000 usd
CY2023Q2 pirs Decrease In Contract With Customer Liability
DecreaseInContractWithCustomerLiability
19900000 usd
pirs Decrease In Contract With Customer Liability
DecreaseInContractWithCustomerLiability
21600000 usd
CY2021Q2 us-gaap Grants Receivable
GrantsReceivable
17000000 usd
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
14138000 usd
CY2023Q4 pirs Cash Equivalents And Investments
CashEquivalentsAndInvestments
22194000 usd
CY2024Q2 pirs Longlived Assets Heldforsale Net Book Value
LonglivedAssetsHeldforsaleNetBookValue
0 usd
CY2023Q4 pirs Longlived Assets Heldforsale Net Book Value
LonglivedAssetsHeldforsaleNetBookValue
2188000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3108000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6448000 usd
CY2024Q2 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
528000 usd
CY2023Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
968000 usd
CY2024Q2 pirs Accrued Accounts Payable Current
AccruedAccountsPayableCurrent
701000 usd
CY2023Q4 pirs Accrued Accounts Payable Current
AccruedAccountsPayableCurrent
558000 usd
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1013000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
363000 usd
CY2024Q2 pirs Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
27000 usd
CY2023Q4 pirs Accrued Collaboration Costs Current
AccruedCollaborationCostsCurrent
213000 usd
CY2024Q2 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
5377000 usd
CY2023Q4 pirs Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
8550000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-3590000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
3976000 usd
us-gaap Net Income Loss
NetIncomeLoss
-8482000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9207000 usd
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1299000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1095000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1268000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1014000
CY2024Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2023Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
2000
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1299000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1098000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1268000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1014000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.76
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.63
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-6.69
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.08
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.76
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.62
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-6.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.08
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
500000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
3750000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1320240
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1236688
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
15617
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
13.34
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
500000 usd
us-gaap Operating Lease Payments
OperatingLeasePayments
1100000 usd
CY2024Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
CY2023Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
287000 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
0 usd
us-gaap Operating Lease Cost
OperatingLeaseCost
574000 usd
CY2024Q2 us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
204000 usd
us-gaap Variable Lease Cost
VariableLeaseCost
0 usd
us-gaap Variable Lease Cost
VariableLeaseCost
388000 usd
CY2024Q2 us-gaap Lease Cost
LeaseCost
0 usd
CY2023Q2 us-gaap Lease Cost
LeaseCost
491000 usd
us-gaap Lease Cost
LeaseCost
0 usd
us-gaap Lease Cost
LeaseCost
962000 usd

Files In Submission

Name View Source Status
0001437749-24-026778-index-headers.html Edgar Link pending
0001437749-24-026778-index.html Edgar Link pending
0001437749-24-026778.txt Edgar Link pending
0001437749-24-026778-xbrl.zip Edgar Link pending
a01.jpg Edgar Link pending
ex_682568.htm Edgar Link pending
ex_682569.htm Edgar Link pending
ex_682570.htm Edgar Link pending
ex_682571.htm Edgar Link pending
ex_708983.htm Edgar Link pending
ex_708984.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
pirs-20240630.xsd Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
pirs-20240630_cal.xml Edgar Link unprocessable
pirs-20240630_def.xml Edgar Link unprocessable
pirs20240630_10q.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pirs-20240630_pre.xml Edgar Link unprocessable
pirs20240630_10q_htm.xml Edgar Link completed
pirs-20240630_lab.xml Edgar Link unprocessable